CardioDx Raises $60M in Private Financing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CardioDx today announced it has closed on a $60 million equity round.

The Palo Alto, Calif.-based cardiovascular genomics testing firm said that the funding will be used to expand reimbursement coverage in the US for its Corad CAD, a gene expression test to determine which patients have or don't have coronary artery disease. The test was launched in June 2009 as a laboratory-developed test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.